Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
2017 Seen as a Challenge for Teva (TEVA), But Sticking with 'Buy' - Maxim
November 16, 2016 8:25 AM ESTMaxim Group analyst Gabrielle Zhou lowered her price target on Teva Pharma (NYSE: TEVA) to $52.00 (from $72.00) but maintained a Buy rating following results. The firm sees 2017 as a challenge.
Zhou commented:
Teva reported 3Q16 with total revenues of $5.6B, with $2.9B in generic product revenues, including $887M from the Actavis generic business (transaction completed on Aug. 2, 2016). Total generic revenues increased 26% sequentially, compared to $2.3B in 2Q16. Specialty revenues were $2B, down 10%... MoreJefferies Downgrades Teva Pharma (TEVA) to Hold; Too Many Headwinds
November 16, 2016 6:32 AM ESTJefferies downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $40.00 (from $69.00), saying there are too many headwinds.
Analyst David Steinberg commented, "Our view has changed. We now think there is little over the next year... More
Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim
November 15, 2016 10:26 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results. The analyst said concerns that generic sales are disappearing are overdone.
Chen commented, "TEVA reported a 3Q16 beat, underscoring our belief that its execution is still... More
